Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Debiopharm Takes Up Confirmatory Phase III Trial Of Sanvar

This article was originally published in The Pink Sheet Daily

Executive Summary

The esophageal variceal bleeding treatment received an FDA “approvable” letter in 2004.

You may also be interested in...



GSK’s Rezonic and Debiovision’s Sanvar To Get Advisory Committee Reviews In May

FDA has been digesting both applications for a considerable amount of time.

GSK’s Rezonic and Debiovision’s Sanvar To Get Advisory Committee Reviews In May

FDA has been digesting both applications for a considerable amount of time.

Debiopharm Files Sanvar In France

Swiss-based Debiopharm is seeking European marketing partners for its somatostatin analog Sanvar (vapreotide acetate), the company said July 24

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel